Gatehouse D G, Paes D J
Carcinogenesis. 1983;4(3):347-52. doi: 10.1093/carcin/4.3.347.
The anti-neoplastic agent procarbazine is genetically active in a variety of short term mutagenicity tests, and it also possesses carcinogenic and teratogenic potential. This compound has consistently yielded false negative results in in vitro microbial mutagenicity tests in the presence and absence of mammalian metabolic activation. In this study, procarbazine was not mutagenic in standard and preincubation Ames tests using large S9 concentrations and bacterial test strains devoid of the rfa mutation. The microtitre fluctuation test is a sensitive technique for the detection of bacterial mutagens. Using this assay, procarbazine proved to be a bacterial mutagen after in vitro metabolic activation at concentrations as low as 200 micrograms/ml. Activity was dependent upon liver S9-concentrations which were higher than those usually attained within agar assays, and was only observed when such fractions were derived from aroclor-treated or phenobarbitone plus beta-naphthoflavone treated rat livers. The excision-repair proficient strain E. coli WP2 was equally, if not more, sensitive than the repair deficient strain E. coli WP2 uvrA. Furthermore, the differential mutagenic effects obtained using S. typhimurium strains TA1535, TA1530 and his G46 indicated that the absence of an rfa mutation was essential for procarbazine mutagenesis. Procarbazine was also mutagenic for E. coli D494 in a forward mutation fluctuation assay measuring resistance to ampicillin. In this assay lower concentrations of S9-fraction were sufficient, reflecting the increased sensitivity of the test strain towards the mutagenic metabolites of the drug. In conclusion, the results suggest that rat liver S9-fraction contains only low levels of enzymes capable of activating procarbazine to a mutagen. This may be a result of rapid breakdown during storage, or due to intrinsically low levels in rat liver extracts. Inducing agents appear to increase these levels. The low concentrations of mutagenic species formed in vitro, may only be detectable using a highly sensitive assay such as the microtitre fluctuation test.
抗肿瘤药丙卡巴肼在多种短期致突变性试验中具有遗传活性,并且还具有致癌和致畸潜力。在有和没有哺乳动物代谢活化的情况下,该化合物在体外微生物致突变性试验中一直产生假阴性结果。在本研究中,使用高浓度S9和不含rfa突变的细菌测试菌株,丙卡巴肼在标准和预孵育Ames试验中没有致突变性。微量滴定波动试验是检测细菌诱变剂的灵敏技术。使用该试验,丙卡巴肼在体外代谢活化后,浓度低至200微克/毫升时被证明是一种细菌诱变剂。活性取决于肝脏S9浓度,该浓度高于琼脂试验中通常达到的浓度,并且仅当这些组分来自多氯联苯处理或苯巴比妥加β-萘黄酮处理的大鼠肝脏时才观察到。切除修复 proficient 菌株大肠杆菌WP2即使不比修复缺陷菌株大肠杆菌WP2 uvrA更敏感,也同样敏感。此外,使用鼠伤寒沙门氏菌菌株TA1535、TA1530和his G46获得的不同诱变效应表明,rfa突变的缺失对于丙卡巴肼诱变是必不可少的。在测量对氨苄青霉素抗性的正向突变波动试验中,丙卡巴肼对大肠杆菌D494也具有致突变性。在该试验中,较低浓度的S9组分就足够了,这反映了测试菌株对药物诱变代谢物的敏感性增加。总之,结果表明大鼠肝脏S9组分仅含有低水平的能够将丙卡巴肼激活为诱变剂的酶。这可能是储存期间快速分解的结果,或者是由于大鼠肝脏提取物中固有水平低。诱导剂似乎会增加这些水平。体外形成的诱变剂物种的低浓度可能仅使用高度灵敏的试验如微量滴定波动试验才能检测到。